Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Teva's Igalmi Approved for At-Home Use to Treat Patients With Agitation Due to Mental Disorders

Teva's Igalmi Approved for At-Home Use to Treat Patients With Agitation Due to Mental Disorders

MT newswireMT newswire2026/11/16 13:21
09:21 AM EST, 11/16/2026 (MT Newswires) -- Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals US affiliate said Monday that the US Food and Drug Administration has approved at-home use of Igalmi sublingual film to treat agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorders in adults. The company said the approval makes Igalmi the first FDA-approved treatment for the disorders that can be used at home. Agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorders affects 25% to 40% of patients with those conditions, Teva said, adding that up to 21% of cases can result in an emergency department visit or hospitalization. Teva owns Igalmi as part of its October acquisition of BioXcel Therapeutics' assets.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Equinix (EQIX.US) chosen as the top stock for Citi’s data centers: AI integration accelerates in one year what took the cloud seven years, making interconnected networks the biggest winners

Citigroup maintains a "Buy" rating on Equinix and lists it as a top pick, expecting its recurring revenue to accelerate to 13% by 2027, with a target price of $1,320.

智通财经•2026/11/18 07:21
Equinix (EQIX.US) chosen as the top stock for Citi’s data centers: AI integration accelerates in one year what took the cloud seven years, making interconnected networks the biggest winners

Japan's 20-year government bond auction sees weak demand as bid-to-cover ratio drops sharply to 3.64, marking the lowest demand of the year

Japan's 20-year government bond auction saw weak demand, with the bid-to-cover ratio falling to 3.64 and the tail widening to its largest in a year. The market is concerned about fiscal budget issues and rising yields.

智通财经•2026/11/18 06:52
Japan's 20-year government bond auction sees weak demand as bid-to-cover ratio drops sharply to 3.64, marking the lowest demand of the year